Sai Life

Who are the top shareholders of the Sai Life?

The top shareholders of Sai Life include Tpg Asia Vii Sf Pte Ltd with 24.73%, promoter Mytreyi Kanumuri at 10.64%, mutual funds holding 11.54%, and foreign institutional investors at 12.36%, while individual investors own 7.69%. A small portion of promoter holdings is pledged at 2.6741%.

The top shareholders of Sai Life include a mix of institutional and individual investors. The largest public shareholder is Tpg Asia Vii Sf Pte Ltd, holding 24.73%. Among the promoters, Mytreyi Kanumuri, a partner at Marigold Partners, has the highest stake at 10.64%. Additionally, mutual funds hold 11.54% of the shares through 21 schemes, while foreign institutional investors (FIIs) account for 12.36% with 73 FIIs involved. Individual investors collectively hold 7.69% of the company. The majority of the shareholding is held by non-institutional investors, with a small portion of promoter holdings being pledged at 2.6741%.

how big is Sai Life?

As of Jun 06, Sai Life Sciences Ltd has a market capitalization of 15,316.00 Cr, with recent net sales of 1,854.06 Cr and net profit of 239.76 Cr for the last four quarters. Shareholder's funds are valued at 975.14 Cr, and total assets amount to 2,262.00 Cr.

Market Cap: <BR>As of Jun 06, Sai Life Sciences Ltd has a market capitalization of 15,316.00 Cr, categorizing it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: <BR>For the latest 4 quarters, the company reported a sum of Net Sales of 1,854.06 Cr and a sum of Net Profit of 239.76 Cr. This data is on a Consolidated basis.<BR><BR>Balance Sheet Snapshot: <BR>The Balance Sheet data is also on a Consolidated basis for the reporting period ending Mar'24. Shareholder's Funds are valued at 975.14 Cr, while Total Assets amount to 2,262.00 Cr.

Has Sai Life declared dividend?

No Dividend History Available

Is Sai Life overvalued or undervalued?

As of February 7, 2025, Sai Life is considered overvalued with a "very expensive" rating due to high valuation metrics like a PE ratio of 88.33 and an EV to EBITDA of 38.80, significantly exceeding its peers, despite recent stock performance outpacing the Sensex.

As of 7 February 2025, Sai Life has moved from a grade of "does not qualify" to "very expensive." The company is currently overvalued based on its high valuation metrics, including a PE ratio of 88.33, an EV to EBIT of 57.30, and an EV to EBITDA of 38.80. These figures significantly exceed those of its peers, such as Sun Pharmaceutical Industries Ltd., which has a PE ratio of 35.25 and an EV to EBITDA of 24.91, and Cipla Ltd., which boasts a much lower PE ratio of 22.99 and an EV to EBITDA of 15.93.<BR><BR>In comparison to its industry, Sai Life's valuation appears excessive, particularly when considering its PEG ratio of 0.00, indicating no growth expectations priced into the stock. The company's recent stock performance has outpaced the Sensex, with a 1-week return of 4.16% compared to the Sensex's 1.35%, suggesting some investor optimism despite the high valuation. Overall, given the significant premium over its peers and the valuation grade, Sai Life is deemed overvalued.

Is Sai Life technically bullish or bearish?

As of June 23, 2025, the market trend is neutral with no strong signals, indicating a consolidation phase despite mildly bullish Bollinger Bands.

As of 23 June 2025, the technical trend has changed from mildly bullish to sideways. The current stance is neutral, with no strong bullish or bearish signals present. The MACD and KST indicators show no clear trend on both weekly and monthly time frames. The RSI is also indicating no signal on the weekly and monthly charts. While the Bollinger Bands are mildly bullish on the weekly, the overall lack of definitive trends in the moving averages, Dow Theory, and OBV suggests a consolidation phase. The recent price action, with a decline from the previous close, further supports this neutral outlook.

Who are the peers of the Sai Life?

Sai Life's peers include Alembic Pharma, Concord Biotech, Neuland Labs, Jubilant Pharmo, Natco Pharma, Blue Jet Health, Caplin Point Lab, Sanofi India, and Alivus Life, with varying management risk and growth ratings. Neuland Labs has the highest 1-year return at 69.64%, while Natco Pharma has the lowest at -20.35%.

Peers: The peers of Sai Life are Alembic Pharma, Concord Biotech, Neuland Labs., Jubilant Pharmo, Natco Pharma, Blue Jet Health, Caplin Point Lab, Sanofi India, and Alivus Life.<BR><BR>Quality Snapshot: Excellent management risk is observed at Concord Biotech and Sanofi India, while Good management risk is found at Alembic Pharma, Neuland Labs., Natco Pharma, Blue Jet Health, Caplin Point Lab, and Alivus Life, and Average management risk is noted at Jubilant Pharmo and Sai Life. Growth is rated as Excellent for Concord Biotech and Natco Pharma, Good for Sai Life, Neuland Labs., and Jubilant Pharmo, while Below Average growth is seen at Alembic Pharma, Blue Jet Health, and Alivus Life, and Average growth is noted at Caplin Point Lab. Capital Structure is Excellent for Concord Biotech, Neuland Labs., Natco Pharma, Blue Jet Health, Caplin Point Lab, and Alivus Life, while Good capital structure is observed at Sai Life and Average at Jubilant Pharmo.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Neuland Labs. at 69.64%, while Natco Pharma has the lowest at -20.35%. Sai Life's 1-year return is not available for comparison. Additionally, Natco Pharma and Sanofi India have negative six-month returns.

What does Sai Life do?

Sai Life Sciences Ltd is a mid-cap pharmaceutical and biotechnology company, reporting net sales of ₹5,795 Cr and a net profit of ₹883 Cr for the quarter ending March 2025, with a market cap of ₹16,888 Cr. The company has a P/E ratio of 98.00 and a return on equity of 8.00%.

Overview:<BR>Sai Life Sciences Ltd is a mid-cap company operating in the Pharmaceuticals & Biotechnology industry.<BR><BR>History:<BR>Sai Life Sciences Limited was incorporated in 1999 as 'Sai Dru Syn Laboratories Limited' and later changed its name in 2003. The most recent quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Net Sales: 5,795 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 883 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 16,888 Cr (Mid Cap)<BR><BR>Key Metrics:<BR>P/E: 98.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.08 <BR>Return on Equity: 8.00% <BR>Price to Book: 7.81 <BR><BR>Contact Details:<BR>No Company Details Available <BR>Registrar Address: Not available.

How has been the historical performance of Sai Life?

Sai Life experienced significant financial growth from March 2024 to March 2025, with net sales rising to 1,694.57 Cr and profit after tax increasing to 170.13 Cr. The company improved its operating profit margin to 23.94% and reduced total debt from 710.16 Cr to 128.64 Cr.

Answer:<BR>The historical performance of Sai Life shows significant growth in various financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>Sai Life's consolidated net sales increased from 1,465.18 Cr in March 2024 to 1,694.57 Cr in March 2025, reflecting a strong upward trend in total operating income as well. The company's total expenditure rose to 1,288.91 Cr from 1,179.69 Cr, with notable increases in raw material costs and employee costs. Operating profit (PBDIT) improved significantly, reaching 442.44 Cr, up from 314.58 Cr, while profit before tax also saw a substantial rise to 227.70 Cr from 109.23 Cr. Consequently, profit after tax surged to 170.13 Cr compared to 82.81 Cr the previous year. The operating profit margin increased to 23.94% from 19.48%, and the PAT margin improved to 10.04% from 5.65%. On the balance sheet, total assets grew to 3,145.78 Cr from 2,262.00 Cr, driven by increases in shareholder's funds and cash reserves, which rose to 463.88 Cr from 158.80 Cr. The company also reduced its total debt significantly from 710.16 Cr to 128.64 Cr. Overall, Sai Life demonstrated robust financial growth and improved profitability in the fiscal year ending March 2025.

When is the next results date for Sai Life Sciences Ltd?

The next results date for Sai Life Sciences Ltd is 05 February 2026.

The next results date for Sai Life Sciences Ltd is scheduled for 05 February 2026.

Are Sai Life Sciences Ltd latest results good or bad?

Sai Life Sciences Ltd's latest Q3 FY26 results are strong, with a net profit increase of 86.41% year-on-year and revenue growth of 26.53%. However, the stock's high price-to-earnings ratio of 99 indicates elevated market expectations, which could pose risks if future performance does not meet them.

Sai Life Sciences Ltd's latest results for Q3 FY26 are quite strong, showcasing significant improvements across various financial metrics. The company reported a net profit of ₹100.38 crore, which is an impressive 86.41% increase year-on-year. Revenue also saw robust growth, rising by 26.53% year-on-year to ₹556.46 crore. This growth is complemented by a record-high operating margin of 33.76%, reflecting effective cost management and operational efficiency.<BR><BR>Furthermore, the profit after tax margin improved to 18.04%, up 580 basis points from the previous year, indicating enhanced profitability. The company has now achieved seven consecutive quarters of profitability, marking a significant turnaround from a loss reported in Q2 FY24.<BR><BR>While the results are strong, it’s important to note that the stock is currently trading at a high price-to-earnings ratio of 99 times trailing earnings, which suggests that the market has high expectations for continued growth. This elevated valuation could pose risks if the company fails to meet these expectations in the future.<BR><BR>Overall, the latest results reflect a positive trajectory for Sai Life Sciences, characterized by strong revenue growth, margin expansion, and improved profitability metrics. However, investors should remain cautious about the high valuation and potential volatility in the stock.

Should I buy, sell or hold Sai Life Sciences Ltd?

Which are the latest news on Sai Life?

Why is Sai Life Sciences Ltd falling/rising?

As of 17-Mar, Sai Life Sciences Ltd's stock price has risen to 984.85, reflecting a 0.91% increase. This growth is driven by strong financial performance, consecutive gains, and a significant return over the past year, despite a slight decline in investor participation.

As of 17-Mar, Sai Life Sciences Ltd is experiencing a rise in its stock price, currently at 984.85, reflecting an increase of 8.85 (0.91%). This upward movement can be attributed to several factors. Firstly, the stock has outperformed its sector by 0.74% today and has been on a consecutive gain streak for the last two days, accumulating a total return of 3.51% during this period. <BR><BR>Moreover, the company has demonstrated strong financial performance, with a significant growth in operating profit at an annual rate of 87.31% and a 21.76% increase in operating profit recently. The positive results declared over the last four consecutive quarters, along with a notable increase in net sales of 42.62% for the first nine months, further bolster investor confidence. <BR><BR>Additionally, the stock's performance over the past year has been impressive, generating a return of 39.93%, which is substantially higher than the market's average return of 6.18%. The company's low debt-to-equity ratio of 0.05 times and high institutional holdings at 52.81% indicate a solid financial foundation and strong backing from knowledgeable investors, which can positively influence stock price movements.<BR><BR>Despite a slight decline in investor participation, as indicated by a 22.28% drop in delivery volume compared to the five-day average, the overall market-beating performance and healthy growth metrics contribute to the stock's rising price.

Why is Sai Life Sciences Ltd falling/rising?

As of 18-Mar, Sai Life Sciences Ltd's stock price has risen to 1,015.40, reflecting a 3.1% increase due to strong financial performance, including an 87.31% growth in operating profit and a 30.96% rise in net sales. The stock has outperformed its sector and shows robust investor confidence, despite concerns over high valuation.

As of 18-Mar, Sai Life Sciences Ltd is experiencing a rise in its stock price, currently at 1,015.40, which reflects an increase of 30.55 or 3.1%. This upward movement can be attributed to several positive factors. The stock has outperformed its sector by 2.83% today and has shown consistent gains over the last three days, accumulating a total return of 6.6% during this period. Additionally, the stock reached an intraday high of Rs 1,025.2, marking a 4.1% increase.<BR><BR>The company's strong performance is further supported by its impressive financial metrics. It has reported a significant growth in operating profit at an annual rate of 87.31%, and its net sales for the latest six months have grown by 30.96%, reaching Rs 1,093.93 crore. Furthermore, the company has declared positive results for the last four consecutive quarters, indicating a robust financial health.<BR><BR>Institutional investors hold a substantial stake in the company, with a high institutional ownership of 52.81%, suggesting confidence in the company's fundamentals. The stock has also demonstrated market-beating performance, generating a return of 45.02% over the past year, significantly outperforming the broader market returns.<BR><BR>Despite some concerns regarding a high valuation indicated by a Price to Book Value of 9.4, the overall positive financial results and strong growth prospects appear to be driving investor interest and contributing to the rise in the stock price.

Why is Sai Life Sciences Ltd falling/rising?

As of 19-Mar, Sai Life Sciences Ltd's stock is declining by -0.82% after three days of gains, influenced by a broader sector drop and decreased investor participation. Despite a strong annual return of 42.65%, the stock's high valuation and recent performance are contributing to its current downturn.

As of 19-Mar, Sai Life Sciences Ltd's stock price is currently falling, with a change of -8.3 (-0.82%). This decline follows a trend reversal after three consecutive days of gains. The stock opened with a loss of -2.3% today and reached an intraday low of Rs 992.05. Additionally, the broader sector, Pharmaceuticals & Drugs, has also experienced a decline of -2.11%, which may be contributing to the stock's downward movement.<BR><BR>Despite the recent performance, Sai Life Sciences has shown strong growth over the past year, with a return of 42.65%, significantly outperforming the market benchmark, which returned only 1.22%. However, the stock's current performance is being affected by a decrease in investor participation, as evidenced by a drop in delivery volume of -1.98% compared to the 5-day average. <BR><BR>While the company has a low debt-to-equity ratio and has reported positive financial results over the last four quarters, the stock's valuation is considered very expensive, with a Price to Book Value of 9.4. This high valuation, combined with the recent price drop and sector performance, is likely influencing the current decline in the stock price.

Why is Sai Life Sciences Ltd falling/rising?

As of 20-Mar, Sai Life Sciences Ltd's stock price is at 999.00, down 0.8% recently. Despite strong long-term growth, recent short-term declines and reduced trading volume indicate a cautious outlook among investors.

As of 20-Mar, Sai Life Sciences Ltd's stock price is currently at 999.00, reflecting a decrease of 8.1 points or 0.8%. The stock has been underperforming in the short term, having fallen for the last two consecutive days, resulting in a total decline of 1.62% during this period. Additionally, the stock's performance today has underperformed the sector by 2.5%. <BR><BR>Despite these recent declines, the stock has shown positive performance over longer periods, with a 1-week increase of 4.88% and a 1-month increase of 6.15%. Year-to-date, the stock has risen by 10.13%, significantly outperforming the broader market, which has seen a decline of 12.54% in the same timeframe. Over the past year, the stock has generated a remarkable return of 38.29%, compared to a mere 2.38% decline in the market.<BR><BR>However, there are signs of falling investor participation, as evidenced by a 40.83% drop in delivery volume compared to the 5-day average. This decline in trading activity may contribute to the stock's current price drop. Furthermore, while the stock is trading above its moving averages, the recent performance and reduced investor engagement indicate a potential shift in market sentiment.<BR><BR>In summary, while Sai Life Sciences Ltd has demonstrated strong long-term growth and market-beating performance, recent short-term declines in price and trading volume suggest a cautious outlook among investors, contributing to the stock's current downward movement.

Why is Sai Life Sciences Ltd falling/rising?

As of 23-Mar, Sai Life Sciences Ltd's stock price is at 991.85, down 0.99% after three consecutive days of decline. Despite this short-term drop, the stock has outperformed the Sensex over the past week, month, and year, indicating strong long-term performance amidst recent sector challenges.

As of 23-Mar, Sai Life Sciences Ltd's stock price is currently at 991.85, reflecting a decrease of 9.9 points or 0.99%. The stock has been experiencing a downward trend, having fallen for the last three consecutive days, resulting in a total decline of 2.32% during this period. Today, it opened with a loss of 2.86% and reached an intraday low of Rs 962.1, which is a 3.96% drop from the previous close.<BR><BR>Despite the current decline, the stock has shown resilience in the longer term. Over the past week, it has outperformed the benchmark Sensex, gaining 1.62% while the Sensex fell by 3.72%. Additionally, in the past month, the stock has increased by 2.48%, contrasting with a 12.72% decline in the Sensex. Year-to-date, the stock has risen by 9.34%, while the broader market has seen a drop of 14.70%. Over the past year, Sai Life Sciences Ltd has delivered impressive returns of 36.74%, significantly outperforming the Sensex, which has declined by 5.47%.<BR><BR>The stock's current decline can be attributed to a combination of factors, including a recent drop in investor participation, as evidenced by a 27.25% decrease in delivery volume compared to the five-day average. The overall sector performance, particularly in Pharmaceuticals & Drugs, has also been negative, with a decline of 3.62%. Furthermore, the stock's valuation appears high, with a Price to Book Value of 9.1, which may contribute to investor caution despite the company's strong fundamentals, such as a low debt-to-equity ratio and consistent growth in operating profit.<BR><BR>In summary, while Sai Life Sciences Ltd is currently experiencing a decline in its stock price, it has shown strong performance relative to the market over various time frames, supported by solid financial results and institutional backing. However, recent negative sector trends and reduced investor activity may be influencing the current downward movement.

Why is Sai Life Sciences Ltd falling/rising?

As of 24-Mar, Sai Life Sciences Ltd's stock price is rising to 1,003.90, reflecting a 1.21% increase. This rise follows a trend reversal after three days of decline, supported by strong fundamentals and significant outperformance compared to the broader market.

As of 24-Mar, Sai Life Sciences Ltd's stock price is rising, currently at 1,003.90, reflecting an increase of 12.05 (1.21%). This upward movement can be attributed to several factors. Firstly, the stock has experienced a trend reversal, gaining after three consecutive days of decline. It opened with a significant gain of 2.53% today and reached an intraday high of Rs 1019, which is a 2.74% increase.<BR><BR>Additionally, the stock is performing well compared to the broader market, as evidenced by its positive returns over various periods. For instance, over the past week, the stock has risen by 1.93%, while the Sensex has fallen by 2.63%. In the last month, Sai Life has increased by 6.41%, contrasting with a 9.92% decline in the Sensex. Year-to-date, the stock has gained 10.67%, while the Sensex has dropped 13.09%. Over the past year, Sai Life's stock has generated a remarkable return of 35.48%, significantly outperforming the Sensex, which has seen a decline of 5.02%.<BR><BR>The stock's performance is also supported by strong fundamentals, including a low debt-to-equity ratio of 0.05 times and healthy growth in operating profit, which has increased at an annual rate of 87.31%. The company has consistently declared positive results for the last four quarters, with net sales in the latest six months growing by 30.96%. Furthermore, high institutional holdings at 52.81% suggest confidence from investors who are typically more adept at analyzing company fundamentals.<BR><BR>Despite a slight decline in investor participation, with delivery volume falling by 19.04% against the five-day average, the overall market-beating performance and strong financial indicators contribute to the stock's rising price.

Why is Sai Life Sciences Ltd falling/rising?

As of 25-Mar, Sai Life Sciences Ltd's stock price is rising to 1,015.20, reflecting a 1.41% increase. This growth is driven by strong annual returns, healthy operating profit growth, and increased investor interest, despite a slight sector underperformance.

As of 25-Mar, Sai Life Sciences Ltd's stock price is rising, currently at 1,015.20, with a change of 14.15 (1.41%) upwards. This upward movement can be attributed to several positive factors. The stock has shown a strong performance over the past year, generating a return of 37.37%, significantly outperforming the broader market, which has seen a decline of 3.52% during the same period. <BR><BR>In addition, the company has reported healthy growth in its operating profit, which has increased at an annual rate of 87.31%. The latest financial results indicate a growth in net sales of 30.96% over the last six months, and the company has declared positive results for the last four consecutive quarters. Furthermore, the stock has been gaining momentum, with a 2.35% increase over the last two days and trading above its moving averages across multiple time frames, indicating a bullish trend.<BR><BR>Investor participation has also risen, with delivery volume increasing by 26.67% compared to the five-day average, suggesting growing interest in the stock. Despite a slight underperformance against its sector today, the overall market-beating performance and strong fundamentals, including a low debt-to-equity ratio and high institutional holdings at 52.81%, contribute to the stock's rising price.